KCT0007346Not yet recruiting
Untitled Trial
Study to determine the safety and tolerability of combination therapy of TACE (Transarterial-chemoembolization) and Immunotherapy With the Autologous Killer Cell in patients with hepatocellular carcinoma: An open label study
Bundang CHA General HospitalNot ApplicableKorean Clinical Trial Registry
VerifiedKorean Clinical Trial Registry
Study focus
- Disease/Condition
- Hepatocellular carcinoma
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Bundang CHA General Hospital
- Location
- South Korea
Timeline & enrollment
- Phase
- Not Applicable
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
- Registry
- Korean Clinical Trial Registry
- Trial ID
- KCT0007346
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for KCT0007346 through Pure Global AI's free database. This Not Applicable trial is sponsored by Bundang CHA General Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular carcinoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Korean Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.